研究方向：

抗衰老药物的研发。

教育和工作经历：

2025年9月起    厦门大学公共卫生学院转化医学专业博士研究生，导师：刘刚 教授。

2022年9月-2025年6月     中山大学生物医学工程学院生物医药专业，获硕士学位，导师：赵奕副教授。

2018年9月-2022年6月     福州大学生物科学与工程学院生物医学工程专业，获工学学士学位。

代表性成果：

• Wang, Y.#, Cheng, H., and Liu, G. (2026). Evolution of embolization microspheres from physical occlusion to theranostic modulation in hepatocellular carcinoma treatment. EngMedicine 3.

• Wang, Y.#, Zeng, Y., and Liu, G. (2025). Advanced Microsphere and Hydrogel Platforms for Precision Interventional Therapy of Hepatocellular Carcinoma. Chemistry 31, e02861.

• Wang, Y.#, Fu, H.#, Huang, B., Liang, Z., Shen, Y., Wang, Y., Wu, J., and Zhao, Y. (2024). Hollow mesoporous Prussian blue nanoenzymes as Rapamycin carrier for targeted treatment of ischemia/reperfusion-induced acute kidney injury through pro-mitophagy and oxidative stress alleviation. Chemical Engineering Journal 497, 155684.

• Fu, H.#, Wang, Y.#, Huang, B., Liang, Z., Li, Y., Cao, Z., Wu, J., and Zhao, Y. (2025). Tannic acid‑cerium nanoenzymes serve as broad-spectrum antioxidants to alleviate acute kidney injury by modulating macrophage polarization, mitophagy and endoplasmic reticulum stress. Journal of controlled release: official journal of the Controlled Release Society 380, 892-909.

• Lv, W.#, Wang, Y.#, Fu, H., Liang, Z., Huang, B., Jiang, R., Wu, J., and Zhao, Y. (2024). Recent advances of multifunctional zwitterionic polymers for biomedical application. Acta Biomater 181, 19-45.

• Wang, Y.#, Liang, Z., Liang, Z., Lv, W., Chen, M., and Zhao, Y. (2022). Advancements of Prussian blue-based nanoplatforms in biomedical fields: Progress and perspectives. Journal of controlled release: official journal of the Controlled Release Society 351, 752-778.

获奖情况：